Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 17/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 16/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3434153 | 0.90 | KDM4E (0.44) | DDB1CRBNSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL3436142 | 0.89 | DDB1 (0.45) | DDB1CRBNSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL853339 | 0.84 | SLC6A1 (0.44) | SLC6A4SLC6A2SLC6A3NOS3NOS1 | |
| SCHEMBL3435014 | 0.83 | DDB1 (0.41) | DDB1CRBNSLC6A4SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL6313494 | 0.82 | SLC6A1 (0.43) | SLC6A4SLC6A2SLC6A3NOS3NOS1 | |
| SCHEMBL31209431 | 0.79 | SLC6A4 (0.38) | SLC6A4SLC6A2SLC6A3NOS3NOS1 | |
| SCHEMBL2018812 | 0.78 | — | — | |
| SCHEMBL3950542 | 0.78 | CA12 (0.41) | SLC6A4SLC6A2SLC6A3KCNH2MAPT | |
| SCHEMBL13221613 | 0.78 | CA12 (0.41) | SLC6A4SLC6A2SLC6A3KCNH2MAPT | |
| SCHEMBL8418672 | 0.77 | DDB1 (0.46) | DDB1CRBNKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | DDB1 3850/4885CRBN 1103/4885SLC6A4 2509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.